25 TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 challenges for our industry. By offering a fully integrated model from protein engineering to cell-line development, and onwards to GMP manufacturing under a single organization, Abzena reduces handoffs, maintains data continuity, and meets emerging regulatory expectations, enabling innovative therapies to reach patients sooner. What new products or innovations is your company showcasing at BIO 2025 this year? At BIO 2025, Ecolab Life Sciences is unveiling its Purolite™ AP+50 resin, the latest addition to its high-performance resin toolbox. Designed for bio manufacturers such as CDMOs and biosimilar developers who are focused on cost efficiencies, AP+50 delivers high-capacity monoclonal antibody purification. The resin supports process intensification strategies by allowing more product throughput with less material and lower operational costs, without sacrificing performance or product quality. Ecolab will also be featuring its Bioquell™ Qube system, an advanced hydrogen peroxide vapor (HPV) decontamination unit that provides rapid and effective bio-decontamination in cleanroom environments, with experts on hand to discuss customer challenges. What are you hoping to achieve from the event? The primary goal at BIO International is to amplify awareness of Ecolab Life Sciences as a trusted, long-standing partner to the pharmaceutical and biotech sectors. With more than a century of industry experience, Ecolab provides expertise in navigating manufacturing complexities and regulatory challenges. By showcasing its integrated capabilities, from scalable bioprocessing tools to advanced digital platforms, Ecolab hopes to deepen industry partnerships and drive further adoption of its innovative solutions. How does your company stay ahead of industry trends and developments in the pharmaceutical sector? Ecolab stays at the forefront by continuously investing in product innovation, digital transformation, and global infrastructure. Its patented Jetted resin bead manufacturing technology exemplifies this, producing highly uniform resins that ensure performance consistency and reduce production variability, a critical advantage for regulatory compliance and supply chain stability. Additionally, Ecolab’s advanced digital platforms support real-time data tracking and operational optimization, empowering customers to make faster, data-driven decisions. What challenges are you currently facing in the pharmaceutical market, and how is your organization addressing them? One of the key industry challenges is the demand for faster, more cost-efficient biomanufacturing amid growing complexity and tighter production timelines. Ecolab is addressing this by offering solutions like Purolite AP+50 resin, which supports dual sourcing strategies and process intensification, helping manufacturers boost productivity while minimizing costs and risks. Another challenge is ensuring contamination control in an evolving regulatory environment. Ecolab tackles this through its end-to-end contamination control solutions and disinfection systems, providing robust safeguards that protect product integrity and patient safety. By partnering closely with customers, Ecolab Life Sciences can help customers anticipate and plan for changes in the evolving regulatory landscape. What new products or innovations are you showcasing at BIO 2025 this year? At BIO 2025, we’re focusing on connecting with early- and mid-stage pharmaceutical companies that are looking for the right development partner to help bring their products forward. Our strength lies in supporting liquid formulation and process development — particularly for nasal sprays and sterile injectable dosage forms — and helping clients navigate the path from early concept through clinical manufacturing and ultimately to commercial launch. We understand the unique challenges that come with early and mid-stage development, and we’ve built our services to be flexible and collaborative. One area we’re seeing a lot of interest in is nasal drug delivery, and we’re excited to offer specialized support there, including standalone spray testing services that can be used as part of a full program or independently. These services are especially helpful for companies looking to generate robust performance data early in development. HALEY CROWE Executive Vice President and General Manager Ecolab Life Sciences ERIK KANEPS Vice President of Sales & Marketing Renaissance Lakewood BIO INTERNATIONAL CONVENTION
RkJQdWJsaXNoZXIy MjY2OTA4MA==